Immunocore Holdings (IMCR) Non-Current Assets (2019 - 2026)
Immunocore Holdings' (IMCR) quarterly Non-Current Assets came in at $68.3 million in Q1 2026, down 13.98% year-on-year from $79.4 million in Q1 2025, and up 712.95% quarter-over-quarter from $8.4 million in Q4 2025.
Immunocore Holdings (IMCR) Non-Current Assets (2019 - 2026) Analysis & Trends
Immunocore Holdings has disclosed Non-Current Assets across 8 years of filings, most recently posting $68.3 million for Q1 2026.
- Non-Current Assets for Q1 2026 came in at $68.3 million, down 13.98% year-over-year; the trailing twelve-month figure through Mar 2026 was $307.4 million (up 5.07% YoY), and the FY2025 annual result was $8.4 million, down 84.97% from the prior year.
- Non-Current Assets came in at $68.3 million for Q1 2026 at Immunocore Holdings, up from $8.4 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $80.1 million in Q2 2025 to a low of $8.4 million in Q4 2025.
- The 5-year median for Non-Current Assets is $67.9 million (2024), against an average of $62.9 million.
- Peak annual rise in Non-Current Assets reached 20.42% in 2025, while the deepest fall reached 84.97% in 2025.
- Immunocore Holdings' Non-Current Assets stood at $51.2 million in 2022, then climbed by 8.24% to $55.4 million in 2023, then gained by 0.9% to $55.9 million in 2024, then tumbled by 84.97% to $8.4 million in 2025, then jumped by 712.95% to $68.3 million in 2026.
- The last three Non-Current Assets figures came in at $68.3 million (Q1 2026), $8.4 million (Q4 2025), and $79.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - | 62,953.78 |
| 2 | Belite Bio | 55,234.00 Bn | 55,234.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 17,823.14 Bn | 17,823.14 Bn | - | 4.56 Mn |
| 4 | Legend Biotech | 3,624.50 Bn | 3,624.21 Bn | 242.10 Mn | 486.60 Mn |
| 5 | Akari Therapeutics | 1,745.73 Bn | 1,745.73 Bn | - | 30.30 Mn |
| 6 | Evaxion A | 1,540.85 Bn | 1,540.84 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | 5.18 Mn |
| 8 | Vertex Pharmaceuticals | 112.57 Bn | 105.33 Bn | 2.59 Bn | 14.75 Bn |
| 9 | Abivax | 93.46 Bn | 93.46 Bn | - | 39.71 Mn |
| 10 | Immunocore Holdings | 1.46 Bn | 616.35 Mn | 106.24 Mn | 68.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 68.29 Mn |
| Dec 31, 2025 | 8.40 Mn |
| Sep 30, 2025 | 79.65 Mn |
| Jun 30, 2025 | 80.09 Mn |
| Mar 31, 2025 | 79.38 Mn |
| Dec 31, 2024 | 55.90 Mn |
| Sep 30, 2024 | 78.73 Mn |
| Jun 30, 2024 | 66.51 Mn |
| Mar 31, 2024 | 67.95 Mn |
| Dec 31, 2023 | 55.40 Mn |
| Dec 31, 2022 | 51.18 Mn |
| Dec 31, 2021 | 52.64 Mn |
| Dec 31, 2020 | 58.45 Mn |
| Dec 31, 2019 | 78.90 Mn |